Neratinib (Figure 43) is an irreversible inhibitor of the EGFR, HER2/4 receptor tyrosine kinase, which was approved on 17 July 2017 for use in the treatment of HER2-positive breast cancer [114]. The gene discussed is ERBB2; the disease is breast carcinoma.